ACADEMIC PRESS INC ELSEVIER SCIENCE
-
Publisher Of
-
A multicenter, randomized, phase II study evaluating the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Gynecologic Oncology.
116:S3-S3.
2010
-
Adverse events associated with laparoscopy versus laparotomy in the treatment of stage I endometrial cancer.
Gynecologic Oncology.
116:S147-S147.
2010
-
Gene expression profiling of invasive serous ovarian cancers from formalin-fixed, paraffin-embedded tissues using DASL.
Gynecologic Oncology.
116:S136-S137.
2010
-
Genomic SRC signature and SRC protein expression in ovarian cancers may predict response to the SRC inhibitor dasatinib.
Gynecologic Oncology.
116:S151-S152.
2010
-
Genomic analysis defines biological pathway differences between early- and advanced-stage ovarian cancers.
Gynecologic Oncology.
116:S22-S22.
2010
-
Indolent and aggressive phenotypes of epithelial ovarian cancer: Implications for screening.
Gynecologic Oncology.
116:S107-S107.
2010
-
Projecting the need for gynecologic oncologists for the next 40 years: Not enough, too many or just right?.
Gynecologic Oncology.
116:S52-S53.
2010
-
INFLUENCE OF CROSS-REACTING IMMUNOLOGIC MATERIAL STATUS ON TREATMENT OUTCOMES IN INFANTILE POMPE PATIENTS TREATED WITH RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE.
Molecular Genetics and Metabolism.
98:59-59.
2009
-
LIFE EXPECTANCY AND CAUSE OF DEATH IN MALES AND FEMALES WITH FABRY DISEASE: FINDINGS FROM THE FABRY REGISTRY.
Molecular Genetics and Metabolism.
98:59-59.
2009
-
LONG-TERM SURVIVAL AND CORRECTION OF BIOCHEMICAL ABNORMALITIES FOLLOWING GENE THERAPY IN DOGS WITH GLYCOGEN STORAGE DISEASE TYPE 1A.
Molecular Genetics and Metabolism.
98:45-45.
2009
-
PROGRESS IN THE DEVELOPMENT OF RAAV2/8 VECTOR-MEDIATED, LIVER-DIRECTED GENE THERAPY FOR PHENYLKETONURIA (PKU).
Molecular Genetics and Metabolism.
98:37-37.
2009
-
SULFITE OXIDASE AND MOLYBDENUM COFACTOR DEFICIENCIES: CLINICAL EXPERIENCE OF A DIAGNOSTIC LABORATORY AND LITERATURE REVIEW.
Molecular Genetics and Metabolism.
98:139-139.
2009
-
7-hydroxystaurosporine (UCN-01) is effective in targeting ovarian cancer spheroids.
Gynecologic Oncology.
112:S161-S162.
2009
-
Cost analysis of ovarian cancer chemotherapy based on the use of a chemoresponse assay.
Gynecologic Oncology.
112:S22-S22.
2009
-
Gene signature specific for ovarian clear cell carcinoma is induced by the contents of endometriotic cysts.
Gynecologic Oncology.
112:S132-S132.
2009
-
Genomic predictors of ovarian cancer response to salvage therapy.
Gynecologic Oncology.
112:S133-S133.
2009
-
High poly (ADP-ribose) polymerase (PARP) expression is associated with poor survival in advanced-stage serous ovarian cancer.
Gynecologic Oncology.
112:S107-S107.
2009
-
Imprinted Neuronatin: A potential epigenetie biomarker of ovarian cancer.
Gynecologic Oncology.
112:S135-S135.
2009
-
Intragenic methylation at a novel CTCF binding site is associated with elevated IGF2 expression in serous epithelial ovarian cancer.
Gynecologic Oncology.
112:S138-S138.
2009
-
Loss of GPR54 correlates with stem cell activity in high-grade endometrial cancer.
Gynecologic Oncology.
112:S78-S78.
2009
-
MiRNA patterns in ovarian cancer cell lines: Correlation with serum studies.
Gynecologic Oncology.
112:S115-S116.
2009
-
Minimally invasive staging for endometrial cancer is associated with lower pain, nausea and narcotic use.
Gynecologic Oncology.
112:S80-S80.
2009
-
Ovarian cancer tumor-infiltrating regulatory T cells are associated with a metastatic phenotype.
Gynecologic Oncology.
112:S11-S11.
2009
-
Validation of the MAL gene as a predictor of survival in advanced-stage high-grade serous ovarian cancer.
Gynecologic Oncology.
112:S123-S124.
2009
-
Can screening for ovarian cancer achieve mortality reduction and be cost effective?.
Gynecologic Oncology.
108:S114-S115.
2008
-
Cost effectiveness of annual screening strategies for endometrial cancer.
Gynecologic Oncology.
108:S7-S7.
2008
-
Gene expression analysis of stage I serous and endornetrioid endometrial cancers.
Gynecologic Oncology.
108:S76-S76.
2008
-
Methylation in ovarian cancer is related to poor prognosis and suppression of the transforming growth factor signaling pathway.
Gynecologic Oncology.
108:S104-S104.
2008
-
Microarray analysis defines patterns of gene expression associated with mutation of TP53 in ovarian cancer.
Gynecologic Oncology.
108:S84-S84.
2008
-
Microarray analysis identifies NSC668814 as a potentially active chemotherapeutic agent for platinum-resistant ovarian cancers with TP53 mutations.
Gynecologic Oncology.
108:S72-S72.
2008
-
Microarray analysis of microdissected stage I endometrial cancers reveals gene expression patterns associated with inflammation.
Gynecologic Oncology.
108:S80-S81.
2008
-
Ovarian Cancer Association Consortium analysis of seven candidate ovarian cancer susceptibility polymorphisms.
Gynecologic Oncology.
108:S29-S30.
2008
-
Regulation of angiogenic gene expression in p53 wild type and mutant ovarian cancer cells by hypoxia and radiation.
Gynecologic Oncology.
108:S84-S84.
2008
-
Targeting dormant ovarian cancer cells.
Gynecologic Oncology.
108:S13-S14.
2008
-
Preclinical evaluation of biomarkers for ovarian cancer detection and monitoring for disease recurrence.
Gynecologic Oncology.
104:S12-S12.
2007
-
The role of multimodality adjuvant chemotherapy and radiation in women with advanced-stage endometrial cancer.
Gynecologic Oncology.
104:S6-S6.
2007
-
Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer - Reply.
Gynecologic Oncology.
96:265-266.
2005
-
Contribution of magnetic resonance microscopy in the biologic and mechanistic assessment of carbonyl sulfide neurotoxicity in F344 rats.
Toxicology and Applied Pharmacology.
197:151-152.
2004
-
Increased event-related theta activity during emotional scene encoding.
Brain and Cognition.
51:186-187.
2003
-
Evolution of a well-characterized embryonic promoter: the Endo16 cis-regulatory system of sea urchins..
Developmental Biology.
247:519-519.
2002
-
Corticosteroids may regulate epithelial cell differentiation and Hassall body formation in the thymus..
Clinical Immunology (Orlando, Fla.).
103:S36-S36.
2002
-
Thymic transplantation in complete DiGeorge syndrome..
Clinical Immunology (Orlando, Fla.).
103:S77-S78.
2002
-
Thymus transplantation after immunosuppression with thymoglobulin..
Clinical Immunology (Orlando, Fla.).
103:S88-S88.
2002
-
Zinc alpha-2-glycoprotein contributes to tumor-associated thymic atrophy..
Clinical Immunology (Orlando, Fla.).
103:S36-S37.
2002
-
Patients with atypical X-linked severe combined immunodeficiency (XSCID) may benefit from hematopoietic stem cell gene therapy..
Blood Cells, Molecules, and Diseases.
28:343-343.
2002
-
THE BETA-ADRENERGIC-RECEPTOR - LIGAND-BINDING STUDIES ILLUMINATE THE MECHANISM OF RECEPTOR ADENYLATE-CYCLASE COUPLING.
Current Topics in Membranes and Transport.
18:45-66.
1983
-
REGULATION OF ADENYLATE-CYCLASE BY ADRENERGIC-RECEPTORS
1982
-
CHANGING THE CLINICAL COURSE OF INFANTILE POMPE DISEASE WITH IMMUNE MODULATION STRATEGIES: 12 YEARS OF EXPERIENCE.
Molecular Genetics and Metabolism.
243-243.
2019
-
COMPARATIVE LIVER PATHOLOGY IN GLYCOGEN STORAGE DISEASE TYPE IIIA.
Molecular Genetics and Metabolism.
256-257.
2019
-
EVALUATION OF PLASMA GLUCOSYLSPHINGOSINE AND GALACTOSYLSPHINGOSINE IN PATIENTS WITH GAUCHER DISEASE.
Molecular Genetics and Metabolism.
312-313.
2019
-
LIVER DISEASE PROGRESSION DURING CHILDHOOD IN GLYCOGEN STORAGE DISEASE TYPE III: THE NEED FOR SYSTEMATIC MONITORING.
Molecular Genetics and Metabolism.
273-274.
2019
-
QUANTITATIVE EVALUATION OF WHITE MATTER HYPERINTENSITIES IN THE CENTRAL NERVOUS SYSTEM IN INFANTILE POMPE DISEASE.
Molecular Genetics and Metabolism.
279-279.
2019
-
SUMMARY OF SCREENING DATA FROM 19 PATIENTS WITH LATE-ONSET POMPE DISEASE FOR A PHASE I CLINICAL TRIAL OF AAV VECTOR-MEDIATED GENE THERAPY.
Molecular Genetics and Metabolism.
274-274.
2019
-
CHANGING THE CLINICAL COURSE OF INFANTILE POMPE DISEASE WITH IMMUNE MODULATION STRATEGIES: 12 YEARS OF EXPERIENCE.
Molecular Genetics and Metabolism.
280-280.
2019
-
COMPARATIVE LIVER PATHOLOGY IN GLYCOGEN STORAGE DISEASE TYPE IIIA.
Molecular Genetics and Metabolism.
291-291.
2019
-
EVALUATION OF PLASMA GLUCOSYLSPHINGOSINE AND GALACTOSYLSPHINGOSINE IN PATIENTS WITH GAUCHER DISEASE.
Molecular Genetics and Metabolism.
336-336.
2019
-
LIVER DISEASE PROGRESSION DURING CHILDHOOD IN GLYCOGEN STORAGE DISEASE TYPE III: THE NEED FOR SYSTEMATIC MONITORING.
Molecular Genetics and Metabolism.
305-305.
2019
-
SUMMARY OF SCREENING DATA FROM 19 PATIENTS WITH LATE-ONSET POMPE DISEASE FOR A PHASE I CLINICAL TRIAL OF AAV VECTOR-MEDIATED GENE THERAPY.
Molecular Genetics and Metabolism.
305-306.
2019
-
A FIRST REPORT OF CHOLANGIOCARCINOMA IN GSD I.
Molecular Genetics and Metabolism.
271-271.
2018
-
BEZAFIBRATE TREATMENT ENHANCES EFFICIENCY OF AAV GENE THERAPY ON GLYCOGEN STORAGE DISEASE TYPE IA.
Molecular Genetics and Metabolism.
201-201.
2018
-
CLINICAL COURSE AND OUTCOME IN ADULTS WITH PROPIONIC ACIDEMIA: CASE SERIES.
Molecular Genetics and Metabolism.
271-272.
2018
-
OVERVIEW OF NUCLEIC ACID THERAPIES.
Molecular Genetics and Metabolism.
199-199.
2018
-
DIABETES MELLITUS AND GLYCOGEN STORAGE DISEASE TYPE 1A IN AN ADULT FEMALE: A CASE STUDY.
Molecular Genetics and Metabolism.
277-277.
2016
-
IDENTIFICATION OF MODIFIER GENES OF POMPE DISEASE PHENOTYPE BY VARIANT ANALYSIS OF WHOLE EXOME SEQUENCING DATA.
Molecular Genetics and Metabolism.
272-273.
2016
-
INFUSION-ASSOCIATED REACTIONS AND IMMUNOGENICITY IN THE ADVANCE STUDY OF ALGLUCOSIDASE ALFA PRODUCED AT 4000 L SCALE IN PATIENTS WITH POMPE DISEASE.
Molecular Genetics and Metabolism.
265-265.
2016
-
SMALL FIBER NEUROPATHY IN A COHORT OF PATIENTS WITH GLYCOGEN STORAGE DISEASE TYPE III.
Molecular Genetics and Metabolism.
243-243.
2016
-
A family with X-linked creatine transporter deficiency diagnosed by whole exome sequencing.
Molecular Genetics and Metabolism.
344-345.
2015
-
A hypophosphatasia case series: Odontohypophosphatasia or childhood/adult form?.
Molecular Genetics and Metabolism.
344-344.
2015
-
BIOENGINEERED HUMAN MUSCLE FOR PHYSIOLOGICAL STUDIES AND DISEASE MODELING.
Molecular Genetics and Metabolism.
304-305.
2015
-
Urinary glucose tetrasaccharide concentrations in patients with infantile and late-onset Pompe disease identified by newborn screening.
Molecular Genetics and Metabolism.
321-322.
2015
-
Zinc finger nuclease-induced targeted integration of a glucose-6-phosphatase gene promotes survival in mice with glycogen storage disease type-IA.
Molecular Genetics and Metabolism.
316-316.
2015
-
DRIED BLOOD SPOT ENZYMATIC ASSAYS FOR MPS TYPE IVA (MORQUIO) AND TYPE VI (MAROTEAUX-LAMY) SYNDROMES.
Molecular Genetics and Metabolism.
251-251.
2014
-
OPTIMIZING METABOLIC CONTROL OF GLYCOGEN STORAGE DISEASE TYPE 3 (GSD3): POTENTIAL ROLE FOR MEDIUM CHAIN TRIGLYCERIDES (MCT).
Molecular Genetics and Metabolism.
284-285.
2014
-
Quantitative whole-body muscle MRI, clinical muscle group weakness, and muscle-map correlation in adult patients with Pompe disease.
Molecular Genetics and Metabolism.
S21-S22.
2014
-
A canine model of glycogen storage disease type III.
Molecular Genetics and Metabolism.
355-356.
2012
-
Assessment of urinary globotriaosylsphingosine (lyso-Gb(3)), globotriaosylceramide (gb(3)) by LC-MS/MS in patients with fabry disease.
Molecular Genetics and Metabolism.
364-365.
2012
-
Clinical challenges diagnosing an infant with hypertrophic cardiomyopathy.
Molecular Genetics and Metabolism.
348-349.
2012
-
Hypophosphatasia: Enzyme replacement therapy (ENB-0040) decreases TNSALP substrate accumulation and improves functional outcome in affected adolescents and adults.
Molecular Genetics and Metabolism.
328-329.
2012
-
Long term treatment of glycogen storage disease type IA: Clinical summary of a canine model.
Molecular Genetics and Metabolism.
314-314.
2012
-
Outcomes of isolated liver and simultaneous liver-kidney transplantation in two patients with glycogen storage disease type lb.
Molecular Genetics and Metabolism.
309-310.
2012
-
Quantification of glycosaminoglycans in human urine and mouse tissue by UPLC-MS/MS.
Molecular Genetics and Metabolism.
365-366.
2012
-
Rapamycin is a potential therapy for glycogen storage disease type III.
Molecular Genetics and Metabolism.
364-364.
2012
-
Elevation of guanidinoacetate in the newborn blood spot of a patient with guanidinoacetate methyltransferase deficiency.
Molecular Genetics and Metabolism.
324-324.
2011
-
Metabolic predictors of coagulation abnormalities in glycogen storage disease type 1.
Molecular Genetics and Metabolism.
277-278.
2011
-
Monitoring urinary glucose tetrasaccharide biomarker in patients with infantile and late-onset Pompe disease identified through newborn screening.
Molecular Genetics and Metabolism.
316-317.
2011
-
Novel application of bortezomib in abrogating antibodies against ERT in Pompe disease: A strategy for broad clinical application in diseases treated with therapeutic proteins.
Molecular Genetics and Metabolism.
245-245.
2011
-
The emerging phenotype of long-term infantile Pompe survivors on enzyme replacement therapy.
Molecular Genetics and Metabolism.
250-250.
2011
-
Why 5-methyltetrahydrofolate may be preferred to folinic acid in severe MTHFR deficiency complicated by cerebral folate deficiency. Results of an "n-1-clinical trial".
Molecular Genetics and Metabolism.
278-279.
2011
-
BJORNSTAD SYNDROME IN A BOY WITH SENSORINEURAL HEARING LOSS, PILI TORTI, MENTAL RETARDATION, SEIZURES AND COMPLEX III DEFICIENCY.
Molecular Genetics and Metabolism.
234-234.
2010
-
HIGHLY EFFICACIOUS GENE THERAPY IN THE CANINE MODEL FOR GLYCOGEN STORAGE DISEASE TYPE IA.
Molecular Genetics and Metabolism.
221-222.
2010
-
Metastin-10 suppresses invasion of endometrial cancer cells.
Gynecologic Oncology.
S76-S76.
2010
-
Progressive epigenetic deregulation of insulin-like growth factor 2 in cervical cancer precursors in HIV plus and HIV- patients.
Gynecologic Oncology.
S38-S38.
2010
-
SEVERE NEONATAL LACTIC ACIDOSIS IN A MALE INFANT WITH A PDH E1 ALPHA FRAME SHIFT MUTATION IN THE C-TERMINAL REGION: COULD WE PREDICT THE OUTCOME?.
Molecular Genetics and Metabolism.
213-213.
2010
-
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
Gynecologic Oncology.
S155-S155.
2010
-
THE ROLE OF ANTI-rhGAA ANTIBODY TITERS AND CLINICAL OUTCOMES IN INFANTILE POMPE DISEASE PATIENTS.
Molecular Genetics and Metabolism.
199-199.
2010
-
BIOMARKER ANALYSIS FOR PYRIDOXINE DEPENDENT SEIZURES AND FOLINIC ACID RESPONSIVE SEIZURES.
Molecular Genetics and Metabolism.
131-131.
2009
-
UTILITY OF A URINARY TETRASACCHARIDE AS A BIOMARKER FOR GLYCOGEN STORAGE DISEASE TYPE III.
Molecular Genetics and Metabolism.
39-39.
2009
-
A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.
Gynecologic Oncology.
S12-S13.
2009
-
Early-stage uterine papillary serous carcinoma (UPSC): percentage UPSC, lymphvascular invasion and tumor size are not independent predictors of recurrence.
Gynecologic Oncology.
S72-S73.
2009
-
Improved survival with consolidation chemotherapy after adjuvant paclitaxel and carboplatin in advanced epithelial ovarian cancer.
Gynecologic Oncology.
S135-S136.
2009
-
Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer.
Gynecologic Oncology.
S81-S81.
2009
-
The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma.
Gynecologic Oncology.
S91-S92.
2009
-
Long-term monitoring of patients with infantile-onset pompe disease using a urinary tetrasaccharide biomarker..
Molecular Genetics and Metabolism.
266-267.
2008
-
MAL, a gene associated with survival in epithelial ovarian cancer, is epigenetically regulated.
Gynecologic Oncology.
S125-S125.
2008
-
Prognostic relevance of microvessel density in previously untreated, advanced-stage epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Gynecologic Oncology.
S20-S20.
2008
-
Quantification of 2,3-dinor-F-2-isoprostanes as a biornarker of oxidative stress in urine by UPLC-LC-ESI-MSIMS: A convenient method for highthroughput analysis..
Molecular Genetics and Metabolism.
266-266.
2008
-
Surgical cytoreduction and dose intensity of adjuvant paclitaxel and carboplatin chemotherapy in advanced epithelial ovarian cancer.
Gynecologic Oncology.
S55-S56.
2008
-
Muscle-targeted gene therapy in glycogen storage disease type II with adeno-associated virus serotypes 7, 8, and 9.
Molecular Genetics and Metabolism.
S38-S39.
2008
-
Dried blood spot assay for Pompe disease: diagnostic experience of the duke biochemical genetics laboratory..
Molecular Genetics and Metabolism.
251-252.
2007
-
Highly efficacious gene therapy in glycogen storage disease type Ia (GSD-Ia) with a double-stranded AAV vector..
Molecular Genetics and Metabolism.
255-256.
2007
-
Most early-stage serous ovarian cancers have gene expression profiles predictive of long-term survival.
Gynecologic Oncology.
S15-S16.
2007
-
Phase II study of cetuximab in combination with carboplatin in patients with relapsed platinum-sensitive ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study.
Gynecologic Oncology.
S32-S32.
2007
-
Evidence for visitomotor deficits in developmental dyslexia: Application of the double-step paradigm.
Brain and Cognition.
318-318.
2006
-
Parathyroid and thymus transplantation in complete DiGeorge syndrome..
Clinical Immunology (Orlando, Fla.).
294-295.
2005
-
Recurrent hemophagocytic lymphohistiocytosis syndrome (HLH) in a patient with common variable immune deficiency..
Clinical Immunology (Orlando, Fla.).
290-290.
2005
-
Time course of normalization of T cell receptor repertoire in a complete DiGeorge syndrome patient post-thymus transplantation..
Clinical Immunology (Orlando, Fla.).
285-286.
2005
-
A proximodistal gradient of Fgf signaling defines position-dependent rates of zebrafish fin regeneration..
Developmental Biology.
642-642.
2005
-
FGF9 is required for male germ cell survival..
Developmental Biology.
649-649.
2005
-
Fgf9 signaling is required for Sertoli precursor cells to establish the male pathway..
Developmental Biology.
638-638.
2005
-
Diagnostic value of urinary and plasma glucose tetrasaccharides in infantile and late onset glycogen storage disease type II..
Molecular Genetics and Metabolism.
241-242.
2005
-
Efficacy of an adeno-associated virus (AAV) vector administered to glycogen storage disease type Ia (GSD-Ia) mice at mid-infancy..
Molecular Genetics and Metabolism.
226-227.
2005
-
Prevention of GvHD while preserving GVL effect after selective depletion of host-reactive T cells by photodynamic cell purging..
Blood Cells, Molecules, and Diseases.
191-192.
2004
-
Differential activation of the three nitric oxide synthase isozymes by calmodulin-Troponin c chimeras.
Nitric Oxide.
69-70.
2004
-
Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock.
Nitric Oxide.
39-39.
2004
-
Hand2 and Twist1 interact antagonistically in the vertebrate limb..
Developmental Biology.
590-590.
2004
-
A central role of RNA in developing therapeutic vaccines for cancer and infectious diseases.
Molecular Therapy.
S222-S222.
2004
-
Correction of glycogen storage disease type II (GSD II) with an adeno-associated virus 8 (AAV2/8) vector.
Molecular Therapy.
S265-S266.
2004
-
Correction of glycogen storage disease type II by intramuscular administration of an adeno-associated virus 6 (AAV2/6) vector containing a muscle-specific promoter.
Molecular Therapy.
S329-S330.
2004
-
Development of adeno-associated virus (AAV) vectors for gene therapy in the mouse model for glycogen storage disease type Ia (GSD-Ia).
Molecular Therapy.
S404-S404.
2004
-
Group I intron-mediated trans-splicing revision of mutant p53 RNA transcripts.
Molecular Therapy.
S231-S231.
2004
-
Insertional analyses in rhesus monkey blood cells after non-myeloablative hematopoietic stem cell marking with a therapeutic onco-retroviral vector for X-linked chronic granulomatous disease.
Molecular Therapy.
S350-S350.
2004
-
Role of Vp2 in AAV packaging.
Molecular Therapy.
S7-S7.
2004
-
The transcapsidation of AAV serotypes.
Molecular Therapy.
S8-S8.
2004
-
Universal purification of AAV serotypes 1-5 modified to contain a heparin binding epitope.
Molecular Therapy.
S36-S36.
2004
-
A comparison of mass spectrometry methods for the measurement of creatine and guanidinoacetate in plasma..
Molecular Genetics and Metabolism.
182-182.
2004
-
Elevated chitotriosidase activity in CSF in patients with GM1 and GM2 gangliosidosis: a surrogate marker of disease progression?.
Molecular Genetics and Metabolism.
181-182.
2004
-
Elevated chitotriosidase activity in CSF in patients with tay-Sachs disease: a surrogate marker of disease progression?.
Molecular Genetics and Metabolism.
182-182.
2004
-
COBRA, a GPI-Anchored membrane protein, regulates anisotropic cell expansion during Arabidopsis development..
Developmental Biology.
586-586.
2003
-
Characterization of the C-elegans embryonic regulatory network specified by PAL-1..
Developmental Biology.
527-528.
2003
-
Radial patterning in arabidopsis: A moving target..
Developmental Biology.
523-523.
2003
-
The MADS box gene AGL42 is expressed in the Arabidopsis root meristem and maintains its organization..
Developmental Biology.
573-573.
2003
-
5 ' exon replacement by spliceosome mediated RNA trans-splicing.
Molecular Therapy.
S301-S302.
2003
-
A genetically engineered plasmid encoding a zinc finger VEGF-activating transcription factor induces angiogenesis in the rabbits with hind-limb ischemia.
Molecular Therapy.
S330-S331.
2003
-
Correction of glycogen storage disease type II (GSD II) by intramuscular administration of an adeno-associated virus (AAV) vector pseudotyped as AAV6.
Molecular Therapy.
S391-S391.
2003
-
Corrective gene transfer into bone marrow CD34+cells for adenosine deaminase (ADA) deficiency: Results in four patients after one year of follow-up.
Molecular Therapy.
S448-S449.
2003
-
Discontinuation of PEG-ADA replacement therapy in a patient with ADA-deficiency previously treated with retroviral-mediated, T cell-directed gene therapy.
Molecular Therapy.
S392-S393.
2003
-
Human umbilical cord cells (UCCS) distribute themselves throughout the degenerating human brain but do not transdifferentiate into neural cells..
Experimental Neurology.
96-96.
2003
-
Serial real-time luminescence imaging profiles differential kinetics and biodistibution of transgene expression from AAV serotype 1-5 vectors following adult and neonatal gene transfer.
Molecular Therapy.
S158-S159.
2003
-
Transmembrane transport of marker molecules and cell membrane kinetics during electropermeabilization.
Molecular Therapy.
S64-S64.
2003
-
Analysis of Arabidopsis root pattern formation: Tissue-specific ectopic expression of the "Moving" putative transcription factor short-root..
Developmental Biology.
486-487.
2002
-
Clinical evaluation of retroviral vectors for gene therapy of adenosine deaminase (ADA) deficiency..
Clinical Immunology (Orlando, Fla.).
S42-S42.
2002